Research programme: TCR-gene-transduced autologous lymphocytes - Takara Bio
Alternative Names: RetroNectin® gene therapy - Takara Bio; RetroNectin® TCR gene therapy - Takara Bio; TCR gene therapy - Takara Bio; TCR gene transduced autologous lymphocytes - Takara BioLatest Information Update: 16 Apr 2019
At a glance
- Originator Takara Bio
- Developer Mie University; National Cancer Institute (USA); Takara Bio
- Class Cell therapies; Gene therapies
- Mechanism of Action Gene transference; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 15 Mar 2019 Takara Bio submits Drug Master File to the US FDA for the liquid formulation of RetroNectin GMP grade
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA (Parenteral)